Cyclacel Pharmaceuticals Inc (CYCC)
$1.06
+0.01
(+0.95%)▲
Performance
- $1.03$1.08$1.06
2.83%
Downside
Day's Volatility :4.63%
Upside
1.85%
- $0.59$11.34$1.06
43.96%
Downside
52 Weeks Volatility :94.76%
Upside
90.66%
Returns
| Period | Cyclacel Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -47.0% | 0.0% |
6 Months | -57.43% | 0.0% |
1 Year | -79.22% | 0.0% |
3 Years | -98.77% | -22.3% |
Highlights
Market Capitalization | 2.1M |
Book Value | $0.55 |
Earnings Per Share (EPS) | -15.31 |
PEG Ratio | 0.0 |
Wall Street Target Price | 11.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -91100.0% |
Return On Assets TTM | -102.53% |
Return On Equity TTM | -570.69% |
Revenue TTM | 80.0K |
Revenue Per Share TTM | 0.04 |
Quarterly Revenue Growth YOY | -98.9% |
Gross Profit TTM | -455.0K |
EBITDA | -20.2M |
Diluted Eps TTM | -15.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.13 |
EPS Estimate Next Year | -1.99 |
EPS Estimate Current Quarter | -1.43 |
EPS Estimate Next Quarter | -1.14 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 937.74%
Technicals Summary
Sell
Neutral
Buy
Cyclacel Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cyclacel Pharmaceuticals Inc | -28.62% | -57.43% | -79.22% | -98.77% | -99.16% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc | NA | NA | 0.0 | -3.13 | -5.71 | -1.03 | NA | 0.55 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cyclacel Pharmaceuticals Inc | Buy | $2.1M | -99.16% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cyclacel Pharmaceuticals Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 116.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.0%
Institutional Holdings
Armistice Capital, LLC
6.79%Renaissance Technologies Corp
1.06%Point72 Asset Management, L.P.
0.78%Acadian Asset Management LLC
0.72%UBS Group AG
0.24%Tower Research Capital LLC
0.21%
Company Information
cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.
Organization | Cyclacel Pharmaceuticals Inc |
Employees | 0 |
CEO | Mr. Spiro George Rombotis |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$1.06
+0.95%
Keyarch Acquisition Corp
$1.06
+0.95%
Connexa Sports Technologies Inc
$1.06
+0.95%
Us Value Etf
$1.06
+0.95%
First Wave Biopharma Inc
$1.06
+0.95%
Global X Msci Next Emerging
$1.06
+0.95%
Fat Projects Acquisition Corp
$1.06
+0.95%
Capital Link Global Fintech
$1.06
+0.95%
Applied Uv Inc
$1.06
+0.95%